Quantification of IgG subclass levels in supernatants 10days after coculture of naive CD4+T cells and allogeneic B cells by means of ELISA. lentiviral SAP vector. Functional recovery was exhibited by usingin vitrocytotoxicity and T follicular helper cell function assays alongside tumor clearance in anin vivolymphoblastoid cell line lymphoma xenograft model. == Results == In Sap-deficient mice 20% to 40% engraftment of gene-modified T cells led to significant recovery of germinal center formation and NP-specific antibody responses. Gene-corrected T cells from patients exhibited improved cytotoxicity and T follicular helper cell functionin vitro. Adoptive transfer of gene-corrected cytotoxic T lymphocytes from patients reduced tumor burden to a level comparable with that seen in healthy donor cytotoxic T lymphocytes in anin vivolymphoma model. == Conclusions == These data demonstrate that autologous T-cell gene therapy corrects SAP-dependent defects and might offer an alternative therapeutic option for patients with X-linked lymphoproliferative disease 1. Key words:X-linked lymphoproliferative disease, T-cell gene therapy, follicular helper T cells, T-cell cytotoxicity Abbreviations used:BV, Brilliant Violet; CTL, Cytotoxic T lymphocyte; HLH, Hemophagocytic lymphohistiocytosis; HSCT, Hematopoietic stem cell transplantation; HVS,Herpesvirus saimiri; LCL, Lymphoblastoid cell line; Cyproheptadine hydrochloride MOI, Multiplicity of contamination; NK, Natural killer; NP-CGG, 4-hydroxy-3-nitrophenylacetly conjugated chicken gammaglobulin; PD-1, Programmed cell death protein 1; PE, Phycoerythrin; SAP, SLAM-associated protein; TFH, T follicular helper; XLP, X-linked lymphoproliferative disease X-linked lymphoproliferative disease 1 (XLP1) is usually a severe primary immunodeficiency arising from mutations in theSH2D1Agene, which encodes an Cyproheptadine hydrochloride intracellular adaptor protein called SLAM-associated protein (SAP). The absence of SAP leads Rabbit polyclonal to GHSR to multiple immunologic defects, including impaired T-cell and natural killer (NK) cell cytotoxicity,1,2,3,4lack of NK T-cell development,5,6and defective CD4+T follicular helper (TFH) cell help,7,8,9which leads to abnormal humoral function. The clinical disease phenotype is usually characterized by severe immune dysregulatory phenomena, including abnormalities in immunoglobulin production and T-dependent humoral immune responses, T-cell effector defects leading to hemophagocytic lymphohistiocytosis (HLH), and development of lymphoma. Specific disease manifestations can be treated supportively with replacement immunoglobulin for dysgammaglobulinemia, HLH chemotherapeutic protocols, monoclonal serotherapy for EBV-driven disease, and appropriate chemotherapy regimens for malignancy, but curative treatment for patients with XLP1 is limited to allogeneic hematopoietic stem cell transplantation (HSCT). Results are highly dependent on a good donor match and the absence of active disease at transplantation, with survival decreasing to 50% if patients enter transplantation with HLH.10For more than 2 decades, autologous hematopoietic stem cell gene therapy has been shown to be a successful treatment option for specific immune deficiencies,11and this experience supports the development of therapeutic gene therapy strategies for other monogenic immune deficiencies. In a Sap-deficient mouse model we exhibited correction of cellular and humoral defects through lentivirus-mediated gene transfer into hematopoietic progenitor cells, thereby providing proof of concept for gene therapy in patients with XLP1.12One concern about this approach was that the nonphysiologic expression of SAP in progenitor cell populations after stem cell gene transfer might be associated with certain risks because of the role of SAP as an important signaling molecule and its tightly regulated expression profile. Although no adverse effects were seen when SAP was expressed in HSCs or other hematopoietic compartments in which expression Cyproheptadine hydrochloride is usually limited, we wanted to evaluate whether transfer of gene-corrected T cells can offer a potentially safer treatment option. We evaluated a number of regulatory elements in the context of a hematopoietic stem cell gene therapy approach to provide lineage-specific SAP expression but were unable to identify a promoter capable of affording specificity and sufficient protein expression to restore immune function (unpublished data). Autologous T-cell gene therapy would diminish concerns over ectopic SAP expression and has an established safety profile, with hundreds of patients treated to date for hematologic malignancies in cancer immunotherapy trials and no reported transformational events.13,14,15,16,17Furthermore, important manifestations of XLP1, such as HLH, lymphoma development, and dysgammaglobulinemia, arise from defective T-cell function and would be potentially corrected through this approach. Therefore we sought to investigate whether infusion of gene-modified T cells could Cyproheptadine hydrochloride correct both humoral and cytotoxic immune defects in a Sap-deficient murine model and anin vivotumor model by using corrected cells from patients. Here, for the first time, we show that viral vectormediated gene correction of.